From GlobeNewswire: 2025-05-15 09:32:00

Aura Biosciences, Inc. announces the pricing of a public offering, consisting of shares of common stock and warrants, with gross proceeds expected to be $75.0 million. The offering is set to close on May 16, 2025, and aims to advance clinical programs in various cancer types. Leerink Partners and Evercore ISI are joint bookrunning managers for the offering, with LifeSci Capital as a bookrunning manager. The offering is made under a shelf registration statement filed with the SEC. Aura Biosciences focuses on developing precision therapies for solid tumors to preserve organ function, with lead candidate bel-sar (AU-011) in late-stage development for choroidal melanoma.



Read more at GlobeNewswire: Aura Biosciences Announces Pricing of Public Offering of